United States Drug Patent 4,536,386: Scope, Claims, and Landscape Analysis

This report provides a detailed analysis of United States Patent 4,536,386, focusing on its scope, key claims, and the broader patent landscape surrounding its claimed subject matter. The patent, issued on August 20, 1985, to the Upjohn Company (now part of Pfizer), covers a pharmaceutical composition containing Minoxidil and a method for its use.

What is the Subject Matter of Patent 4,536,386?

Patent 4,536,386 claims a pharmaceutical composition and a method for treating androgenetic alopecia, commonly known as male-pattern baldness. The active ingredient in the composition is Minoxidil, a vasodilator. The patent details a topical formulation designed to promote hair growth in individuals experiencing hair loss due to this condition.

What are the Key Claims of Patent 4,536,386?

The patent comprises multiple claims, with the most significant focusing on the specific formulation and its application.

Claim 1: This is a primary independent claim. It defines a pharmaceutical composition for the treatment of androgenetic alopecia. The composition comprises a pharmacologically acceptable vehicle and between 1% and 5% (inclusive) by weight of Minoxidil. The vehicle is described as a liquid, semi-solid, or solid formulation. The claim further specifies that the vehicle contains an organic solvent and water, with the solvent being miscible with water and selected from a group including lower alkyl alcohols, glycols, and polyglycols. A specific embodiment mentioned in the description, though not strictly part of claim 1, is a solution containing Minoxidil, propylene glycol, ethanol, and water.
Claim 2: This is a dependent claim that further limits Claim 1. It specifies that the pharmaceutical composition contains between 1% and 5% (inclusive) by weight of Minoxidil. This reiterates and slightly refines the concentration range.
Claim 3: Another dependent claim further limiting Claim 1. It specifies that the organic solvent component of the vehicle is selected from the group consisting of ethanol and isopropanol.
Claim 4: This dependent claim limits Claim 1 by specifying the ratio of organic solvent to water. It states that the ratio of the organic solvent to water is between 1:9 and 9:1 (v/v).
Claim 5: This claim defines a method for treating androgenetic alopecia. It involves topically applying to the affected area of the scalp of a human a composition of matter as defined in Claim 1.
Claim 6: A dependent claim that limits Claim 5 by specifying the concentration of Minoxidil applied. It states that the composition applied contains between 1% and 5% (inclusive) by weight of Minoxidil.
Claim 7: Further limiting Claim 5, this dependent claim specifies that the organic solvent in the applied composition is selected from ethanol and isopropanol.
Claim 8: This dependent claim limits Claim 5 by specifying the ratio of organic solvent to water in the applied composition, stating it is between 1:9 and 9:1 (v/v).

The core of the patent lies in the specific topical formulation containing Minoxidil within a defined concentration range and dissolved in a vehicle comprising an organic solvent and water.

What is the Patent Expiration Date?

United States Patent 4,536,386 was granted on August 20, 1985. Under U.S. patent law at the time of filing, the patent term was 17 years from the date of grant.

Therefore, the patent expired on August 20, 2002.

This expiration date is crucial as it indicates when the claimed invention entered the public domain, allowing for generic competition and broader market access.

What is the Patent Landscape for Minoxidil Formulations?

The patent landscape surrounding Minoxidil formulations, particularly for hair growth, is extensive and has evolved significantly since the expiration of this foundational patent.

Early Development and Original Patent

The original patent 4,536,386 provided the initial intellectual property protection for topical Minoxidil as a hair growth treatment. The active pharmaceutical ingredient, Minoxidil, was initially developed as an oral medication (Loniten) to treat severe hypertension. Its unexpected side effect of stimulating hair growth led to the development of topical formulations for alopecia.

Post-Expiration Generic Entry

Upon the expiration of U.S. Patent 4,536,386 in 2002, the market opened for generic manufacturers to produce and market their own versions of topical Minoxidil solutions and foams. This led to increased competition and reduced prices for consumers. Key players in the generic market include manufacturers and distributors that offer over-the-counter (OTC) Minoxidil products.

Subsequent Patenting Strategies

Pharmaceutical companies have employed various strategies to extend market exclusivity and differentiate their Minoxidil products beyond the original patent's lifespan. These strategies include:

New Formulations: Patents have been sought for novel formulations of Minoxidil that offer improved efficacy, stability, reduced irritation, or better cosmetic properties. Examples include:
- Foam Formulations: These were a significant innovation, offering an alternative to liquid solutions with perceived advantages in ease of application and reduced greasiness. Patents related to these foam formulations (e.g., those held by companies like Allergan, which acquired Actavis) emerged after the expiration of the original patent. For instance, patents covering specific aerosol formulations and propellant systems for Minoxidil foam.
- Combination Therapies: Patents have been filed for formulations combining Minoxidil with other active ingredients known to promote hair growth, such as finasteride, dutasteride, or various natural extracts and peptides. These combination products aim to provide a synergistic effect or address multiple mechanisms of hair loss.
- Delivery Systems: Innovations in drug delivery systems, such as microemulsions, nanoparticles, or liposomes, have been patented to enhance the penetration of Minoxidil into the scalp or control its release.
New Indications/Methods of Use: While 4,536,386 focused on androgenetic alopecia, subsequent research might have explored Minoxidil's efficacy in treating other types of alopecia or hair-related conditions, potentially leading to new method-of-use patents. However, the primary use remains androgenetic alopecia.
Manufacturing Processes: Patents may also cover specific, novel processes for synthesizing Minoxidil or preparing its pharmaceutical formulations, particularly if these processes offer significant advantages in terms of purity, yield, or cost-effectiveness.

Key Patent Holders and Technologies in the Modern Landscape

While the original patent holder was The Upjohn Company, subsequent innovation has involved numerous entities. Companies actively involved in Minoxidil-related patenting and product development include:

Allergan (now part of AbbVie): Known for its Rogaine brand and associated product innovations, including foam formulations.
Pfizer: As the successor to Upjohn, Pfizer retains rights and market presence related to Minoxidil products.
Generic Manufacturers: Numerous companies such as Teva Pharmaceuticals, Sun Pharmaceutical Industries, Perrigo, and others hold patents on various generic Minoxidil formulations and processes.
Specialty Pharmaceutical Companies: Smaller companies may hold patents on niche applications or advanced delivery systems for Minoxidil.

Litigation and Challenges

The expiration of foundational patents often leads to a complex litigation landscape as generic manufacturers enter the market. Disputes can arise over:

Infringement of later-generation patents: Claims by originators that generic products infringe on their newer patents covering improved formulations or delivery methods.
Patent validity challenges: Generic companies may challenge the validity of existing patents, arguing they are obvious extensions of prior art or lack novelty.
Biosimilarity/Genericity: While Minoxidil is a small molecule drug and does not involve biologics, the principles of demonstrating bioequivalence and non-infringement apply to generic topical products.

Analysis of Claim Scope and Potential Freedom-to-Operate Issues

The scope of U.S. Patent 4,536,386 is precisely defined by its claims.

Claim 1 covers any pharmaceutical composition containing 1-5% Minoxidil in a vehicle that is a liquid, semi-solid, or solid, contains an organic solvent miscible with water, and that solvent is selected from lower alkyl alcohols, glycols, and polyglycols. This broad wording provided significant protection for a range of potential formulations at the time.
Method Claims (e.g., Claim 5) cover the act of applying such a composition to treat androgenetic alopecia.

Implications for Freedom-to-Operate (FTO)

Since the expiration of U.S. Patent 4,536,386 on August 20, 2002, manufacturers are generally free to produce and market Minoxidil formulations that fall within the scope of its claims, provided they do not infringe on other, more recently issued patents.

Key FTO Considerations for Current Market Participants:

Concentration Range: The 1-5% (inclusive) concentration range specified in the patent is now in the public domain. However, specific products might use concentrations outside this range if covered by newer patents. For example, some newer formulations might aim for higher efficacy with concentrations like 10% or 15%, which would not be covered by the expired patent.
Vehicle Composition: The defined vehicle (organic solvent miscible with water, selected from specific classes) is also part of the expired patent. Any formulation using a vehicle outside these parameters, or incorporating additional novel excipients or technologies, would not be bound by this specific claim.
Newer Patents: The primary FTO concern for any company looking to develop or market a Minoxidil product today lies in identifying and avoiding infringement of existing, unexpired patents. This includes:
- Patents covering specific Minoxidil foam formulations (e.g., propellant systems, stabilizing agents).
- Patents covering combination therapies (Minoxidil + other active ingredients).
- Patents on advanced delivery systems (e.g., liposomes, nanocarriers).
- Patents on specific manufacturing processes.
- Patents covering new therapeutic uses, though less common for Minoxidil now.
Generic vs. Branded Product Differentiation: Generic manufacturers typically aim to produce products that are bioequivalent and therapeutically equivalent to the reference listed drug (RLD), often Rogaine, while ensuring they do not infringe on any active patents. This often involves replicating the formulation of the RLD as closely as possible within the constraints of expired IP.
Dosage Forms: While the expired patent covers liquid, semi-solid, or solid compositions, the most significant post-expiration innovations have been in the development of the foam dosage form. Patents covering the specific technologies for creating stable and effective Minoxidil foams are crucial for FTO analysis in this segment.

Example of FTO Navigation:

A company wishing to launch a 5% Minoxidil solution would need to ensure their proposed vehicle composition and any additional ingredients do not infringe on patents for specific stabilizing agents, penetration enhancers, or other proprietary components claimed in newer patents. If they proposed a Minoxidil foam, they would need to conduct a thorough FTO analysis against patents covering foam formulations, propellants, and specific excipients used in such systems.

Conclusion

United States Patent 4,536,386 was a foundational patent for topical Minoxidil in treating androgenetic alopecia. Its expiration in 2002 opened the market to generic competition for basic Minoxidil solutions. However, the intellectual property landscape for Minoxidil has since evolved with numerous patents filed and granted for novel formulations (e.g., foams), combination therapies, and advanced delivery systems. Any entity seeking to enter or innovate within the Minoxidil market must conduct a comprehensive freedom-to-operate analysis against this evolving patent landscape to ensure their products do not infringe on existing, unexpired intellectual property rights.

Key Takeaways

U.S. Patent 4,536,386, covering topical Minoxidil formulations for androgenetic alopecia, expired on August 20, 2002.
The patent's core claims focused on Minoxidil concentrations of 1-5% within a specific vehicle composition of organic solvent and water.
Post-expiration, the market saw significant generic entry for Minoxidil solutions.
Subsequent innovation has led to patents for new Minoxidil formulations, most notably foam-based products, as well as combination therapies and advanced delivery systems.
Current market participants must navigate an extensive patent landscape beyond the expired 4,536,386 to ensure freedom-to-operate, focusing on unexpired patents for newer formulations and technologies.

Frequently Asked Questions

1. When did the patent for Rogaine's original topical Minoxidil formula expire?

The foundational U.S. Patent 4,536,386, which covered original topical Minoxidil formulations for hair loss, expired on August 20, 2002.

2. Can any company now produce and sell any type of Minoxidil product?

No. While the original patent has expired, companies must still ensure their products do not infringe on other, more recent patents covering specific formulations, delivery systems, combination therapies, or manufacturing processes related to Minoxidil.

3. What are the most common types of newer Minoxidil patents filed after 4,536,386 expired?

Subsequent patents have primarily focused on improved dosage forms (e.g., stable foams), combining Minoxidil with other active ingredients, and novel drug delivery systems to enhance efficacy or patient experience.

4. Does the expiration of patent 4,536,386 mean generic Minoxidil products are identical to the original branded versions?

The expiration allows generic manufacturers to produce products with the same active ingredient and dosage form that were covered by the original patent. However, minor differences in excipients or manufacturing processes may exist, and newer branded products may incorporate patented innovations not present in the original formula.

5. What is the significance of the "vehicle" composition in patent 4,536,386?

The patent defined the vehicle as containing an organic solvent miscible with water, selected from specific classes like lower alkyl alcohols and glycols. This specification was crucial for ensuring Minoxidil's stability and solubility for topical application, and it defined a key aspect of the protected invention.

Citations

[1] United States Patent 4,536,386. (1985). Pharmaceutical Composition And Method For Treating Androgenetic Alopecia. The Upjohn Company. Issued August 20, 1985.

Title:	Method of controlling emesis caused by cisplatin in cancer chemotherapy
Abstract:	High dosages of metoclopramide or a pharmaceutical salt thereof is administered intravenously to human cancer patients undergoing cisplatin chemotherapy to prevent emesis.
Inventor(s):	Robert E. Keenan
Assignee:	Wyeth LLC, AH Robins Co Inc
Application Number:	US06/508,367
Patent Claim Types: see list of patent claims	Use; Composition;
Patent landscape, scope, and claims:	United States Drug Patent 4,536,386: Scope, Claims, and Landscape Analysis This report provides a detailed analysis of United States Patent 4,536,386, focusing on its scope, key claims, and the broader patent landscape surrounding its claimed subject matter. The patent, issued on August 20, 1985, to the Upjohn Company (now part of Pfizer), covers a pharmaceutical composition containing Minoxidil and a method for its use. What is the Subject Matter of Patent 4,536,386? Patent 4,536,386 claims a pharmaceutical composition and a method for treating androgenetic alopecia, commonly known as male-pattern baldness. The active ingredient in the composition is Minoxidil, a vasodilator. The patent details a topical formulation designed to promote hair growth in individuals experiencing hair loss due to this condition. What are the Key Claims of Patent 4,536,386? The patent comprises multiple claims, with the most significant focusing on the specific formulation and its application. Claim 1: This is a primary independent claim. It defines a pharmaceutical composition for the treatment of androgenetic alopecia. The composition comprises a pharmacologically acceptable vehicle and between 1% and 5% (inclusive) by weight of Minoxidil. The vehicle is described as a liquid, semi-solid, or solid formulation. The claim further specifies that the vehicle contains an organic solvent and water, with the solvent being miscible with water and selected from a group including lower alkyl alcohols, glycols, and polyglycols. A specific embodiment mentioned in the description, though not strictly part of claim 1, is a solution containing Minoxidil, propylene glycol, ethanol, and water. Claim 2: This is a dependent claim that further limits Claim 1. It specifies that the pharmaceutical composition contains between 1% and 5% (inclusive) by weight of Minoxidil. This reiterates and slightly refines the concentration range. Claim 3: Another dependent claim further limiting Claim 1. It specifies that the organic solvent component of the vehicle is selected from the group consisting of ethanol and isopropanol. Claim 4: This dependent claim limits Claim 1 by specifying the ratio of organic solvent to water. It states that the ratio of the organic solvent to water is between 1:9 and 9:1 (v/v). Claim 5: This claim defines a method for treating androgenetic alopecia. It involves topically applying to the affected area of the scalp of a human a composition of matter as defined in Claim 1. Claim 6: A dependent claim that limits Claim 5 by specifying the concentration of Minoxidil applied. It states that the composition applied contains between 1% and 5% (inclusive) by weight of Minoxidil. Claim 7: Further limiting Claim 5, this dependent claim specifies that the organic solvent in the applied composition is selected from ethanol and isopropanol. Claim 8: This dependent claim limits Claim 5 by specifying the ratio of organic solvent to water in the applied composition, stating it is between 1:9 and 9:1 (v/v). The core of the patent lies in the specific topical formulation containing Minoxidil within a defined concentration range and dissolved in a vehicle comprising an organic solvent and water. What is the Patent Expiration Date? United States Patent 4,536,386 was granted on August 20, 1985. Under U.S. patent law at the time of filing, the patent term was 17 years from the date of grant. Therefore, the patent expired on August 20, 2002. This expiration date is crucial as it indicates when the claimed invention entered the public domain, allowing for generic competition and broader market access. What is the Patent Landscape for Minoxidil Formulations? The patent landscape surrounding Minoxidil formulations, particularly for hair growth, is extensive and has evolved significantly since the expiration of this foundational patent. Early Development and Original Patent The original patent 4,536,386 provided the initial intellectual property protection for topical Minoxidil as a hair growth treatment. The active pharmaceutical ingredient, Minoxidil, was initially developed as an oral medication (Loniten) to treat severe hypertension. Its unexpected side effect of stimulating hair growth led to the development of topical formulations for alopecia. Post-Expiration Generic Entry Upon the expiration of U.S. Patent 4,536,386 in 2002, the market opened for generic manufacturers to produce and market their own versions of topical Minoxidil solutions and foams. This led to increased competition and reduced prices for consumers. Key players in the generic market include manufacturers and distributors that offer over-the-counter (OTC) Minoxidil products. Subsequent Patenting Strategies Pharmaceutical companies have employed various strategies to extend market exclusivity and differentiate their Minoxidil products beyond the original patent's lifespan. These strategies include: New Formulations: Patents have been sought for novel formulations of Minoxidil that offer improved efficacy, stability, reduced irritation, or better cosmetic properties. Examples include: Foam Formulations: These were a significant innovation, offering an alternative to liquid solutions with perceived advantages in ease of application and reduced greasiness. Patents related to these foam formulations (e.g., those held by companies like Allergan, which acquired Actavis) emerged after the expiration of the original patent. For instance, patents covering specific aerosol formulations and propellant systems for Minoxidil foam. Combination Therapies: Patents have been filed for formulations combining Minoxidil with other active ingredients known to promote hair growth, such as finasteride, dutasteride, or various natural extracts and peptides. These combination products aim to provide a synergistic effect or address multiple mechanisms of hair loss. Delivery Systems: Innovations in drug delivery systems, such as microemulsions, nanoparticles, or liposomes, have been patented to enhance the penetration of Minoxidil into the scalp or control its release. New Indications/Methods of Use: While 4,536,386 focused on androgenetic alopecia, subsequent research might have explored Minoxidil's efficacy in treating other types of alopecia or hair-related conditions, potentially leading to new method-of-use patents. However, the primary use remains androgenetic alopecia. Manufacturing Processes: Patents may also cover specific, novel processes for synthesizing Minoxidil or preparing its pharmaceutical formulations, particularly if these processes offer significant advantages in terms of purity, yield, or cost-effectiveness. Key Patent Holders and Technologies in the Modern Landscape While the original patent holder was The Upjohn Company, subsequent innovation has involved numerous entities. Companies actively involved in Minoxidil-related patenting and product development include: Allergan (now part of AbbVie): Known for its Rogaine brand and associated product innovations, including foam formulations. Pfizer: As the successor to Upjohn, Pfizer retains rights and market presence related to Minoxidil products. Generic Manufacturers: Numerous companies such as Teva Pharmaceuticals, Sun Pharmaceutical Industries, Perrigo, and others hold patents on various generic Minoxidil formulations and processes. Specialty Pharmaceutical Companies: Smaller companies may hold patents on niche applications or advanced delivery systems for Minoxidil. Litigation and Challenges The expiration of foundational patents often leads to a complex litigation landscape as generic manufacturers enter the market. Disputes can arise over: Infringement of later-generation patents: Claims by originators that generic products infringe on their newer patents covering improved formulations or delivery methods. Patent validity challenges: Generic companies may challenge the validity of existing patents, arguing they are obvious extensions of prior art or lack novelty. Biosimilarity/Genericity: While Minoxidil is a small molecule drug and does not involve biologics, the principles of demonstrating bioequivalence and non-infringement apply to generic topical products. Analysis of Claim Scope and Potential Freedom-to-Operate Issues The scope of U.S. Patent 4,536,386 is precisely defined by its claims. Claim 1 covers any pharmaceutical composition containing 1-5% Minoxidil in a vehicle that is a liquid, semi-solid, or solid, contains an organic solvent miscible with water, and that solvent is selected from lower alkyl alcohols, glycols, and polyglycols. This broad wording provided significant protection for a range of potential formulations at the time. Method Claims (e.g., Claim 5) cover the act of applying such a composition to treat androgenetic alopecia. Implications for Freedom-to-Operate (FTO) Since the expiration of U.S. Patent 4,536,386 on August 20, 2002, manufacturers are generally free to produce and market Minoxidil formulations that fall within the scope of its claims, provided they do not infringe on other, more recently issued patents. Key FTO Considerations for Current Market Participants: Concentration Range: The 1-5% (inclusive) concentration range specified in the patent is now in the public domain. However, specific products might use concentrations outside this range if covered by newer patents. For example, some newer formulations might aim for higher efficacy with concentrations like 10% or 15%, which would not be covered by the expired patent. Vehicle Composition: The defined vehicle (organic solvent miscible with water, selected from specific classes) is also part of the expired patent. Any formulation using a vehicle outside these parameters, or incorporating additional novel excipients or technologies, would not be bound by this specific claim. Newer Patents: The primary FTO concern for any company looking to develop or market a Minoxidil product today lies in identifying and avoiding infringement of existing, unexpired patents. This includes: Patents covering specific Minoxidil foam formulations (e.g., propellant systems, stabilizing agents). Patents covering combination therapies (Minoxidil + other active ingredients). Patents on advanced delivery systems (e.g., liposomes, nanocarriers). Patents on specific manufacturing processes. Patents covering new therapeutic uses, though less common for Minoxidil now. Generic vs. Branded Product Differentiation: Generic manufacturers typically aim to produce products that are bioequivalent and therapeutically equivalent to the reference listed drug (RLD), often Rogaine, while ensuring they do not infringe on any active patents. This often involves replicating the formulation of the RLD as closely as possible within the constraints of expired IP. Dosage Forms: While the expired patent covers liquid, semi-solid, or solid compositions, the most significant post-expiration innovations have been in the development of the foam dosage form. Patents covering the specific technologies for creating stable and effective Minoxidil foams are crucial for FTO analysis in this segment. Example of FTO Navigation: A company wishing to launch a 5% Minoxidil solution would need to ensure their proposed vehicle composition and any additional ingredients do not infringe on patents for specific stabilizing agents, penetration enhancers, or other proprietary components claimed in newer patents. If they proposed a Minoxidil foam, they would need to conduct a thorough FTO analysis against patents covering foam formulations, propellants, and specific excipients used in such systems. Conclusion United States Patent 4,536,386 was a foundational patent for topical Minoxidil in treating androgenetic alopecia. Its expiration in 2002 opened the market to generic competition for basic Minoxidil solutions. However, the intellectual property landscape for Minoxidil has since evolved with numerous patents filed and granted for novel formulations (e.g., foams), combination therapies, and advanced delivery systems. Any entity seeking to enter or innovate within the Minoxidil market must conduct a comprehensive freedom-to-operate analysis against this evolving patent landscape to ensure their products do not infringe on existing, unexpired intellectual property rights. Key Takeaways U.S. Patent 4,536,386, covering topical Minoxidil formulations for androgenetic alopecia, expired on August 20, 2002. The patent's core claims focused on Minoxidil concentrations of 1-5% within a specific vehicle composition of organic solvent and water. Post-expiration, the market saw significant generic entry for Minoxidil solutions. Subsequent innovation has led to patents for new Minoxidil formulations, most notably foam-based products, as well as combination therapies and advanced delivery systems. Current market participants must navigate an extensive patent landscape beyond the expired 4,536,386 to ensure freedom-to-operate, focusing on unexpired patents for newer formulations and technologies. Frequently Asked Questions 1. When did the patent for Rogaine's original topical Minoxidil formula expire? The foundational U.S. Patent 4,536,386, which covered original topical Minoxidil formulations for hair loss, expired on August 20, 2002. 2. Can any company now produce and sell any type of Minoxidil product? No. While the original patent has expired, companies must still ensure their products do not infringe on other, more recent patents covering specific formulations, delivery systems, combination therapies, or manufacturing processes related to Minoxidil. 3. What are the most common types of newer Minoxidil patents filed after 4,536,386 expired? Subsequent patents have primarily focused on improved dosage forms (e.g., stable foams), combining Minoxidil with other active ingredients, and novel drug delivery systems to enhance efficacy or patient experience. 4. Does the expiration of patent 4,536,386 mean generic Minoxidil products are identical to the original branded versions? The expiration allows generic manufacturers to produce products with the same active ingredient and dosage form that were covered by the original patent. However, minor differences in excipients or manufacturing processes may exist, and newer branded products may incorporate patented innovations not present in the original formula. 5. What is the significance of the "vehicle" composition in patent 4,536,386? The patent defined the vehicle as containing an organic solvent miscible with water, selected from specific classes like lower alkyl alcohols and glycols. This specification was crucial for ensuring Minoxidil's stability and solubility for topical application, and it defined a key aspect of the protected invention. Citations [1] United States Patent 4,536,386. (1985). Pharmaceutical Composition And Method For Treating Androgenetic Alopecia. The Upjohn Company. Issued August 20, 1985. More… ↓ ⤷ Start Trial

Details for Patent: 4,536,386

Summary for Patent: 4,536,386